Phio Pharmaceuticals Corp (PHIO) — Cash Flow-to-Debt Ratio
Phio Pharmaceuticals Corp (PHIO) has a Cash Flow-to-Debt Ratio of -4.21x as of March 2026, meaning its operating cash flow of $-4.00 Million could theoretically repay -4% of its total liabilities ($950.00K) in one year. See PHIO working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Phio Pharmaceuticals Corp Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Phio Pharmaceuticals Corp across 15 annual periods. Also explore Phio Pharmaceuticals Corp net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Phio Pharmaceuticals Corp (2011–2025)
Year-by-year debt coverage analysis for Phio Pharmaceuticals Corp. For market capitalisation and broader financial context, see Phio Pharmaceuticals Corp (PHIO) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.95x | $-7.98 Million | $1.34 Million | ▲ +15.0% |
| 2024 | -7.01x | $-7.11 Million | $1.01 Million | ▼ -6.5% |
| 2023 | -6.58x | $-10.75 Million | $1.63 Million | ▼ -7.1% |
| 2022 | -6.14x | $-12.13 Million | $1.97 Million | ▼ -67.8% |
| 2021 | -3.66x | $-11.86 Million | $3.24 Million | ▼ -13.3% |
| 2020 | -3.23x | $-8.80 Million | $2.72 Million | ▲ +14.3% |
| 2019 | -3.77x | $-8.64 Million | $2.29 Million | ▲ +12.5% |
| 2018 | -4.31x | $-7.52 Million | $1.74 Million | ▼ -2.7% |
| 2017 | -4.20x | $-9.51 Million | $2.27 Million | ▼ -37.6% |
| 2016 | -3.05x | $-7.76 Million | $2.54 Million | ▲ +5.3% |
| 2015 | -3.22x | $-7.32 Million | $2.27 Million | ▼ -167.9% |
| 2014 | -1.20x | $-7.76 Million | $6.44 Million | ▼ -90.7% |
| 2013 | -0.63x | $-6.31 Million | $10.00 Million | ▼ -42.6% |
| 2012 | -0.44x | $-5.06 Million | $11.43 Million | ▲ +89.9% |
| 2011 | -4.38x | $-9.99 Million | $2.28 Million | — |